Stunning: Untoward effect of 131I thyroid imaging prior to radioablation therapy

Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management

Volumn , Issue , 2006, Pages 337-345

  Park, Hee Myung ^a,b   Gerard, Stephen K ^c  

^a INDIANA UNIVERSITY   (United States)

^b Catholic Kwandong University   (South Korea)

^c Seton Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33751062502     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-995-0_36     Document Type: Chapter

References (42)

1. Park HM. I-123: Almost a designer radioiodine for thyroid scanning. J Nucl Med 2002; 43:77-78.
2. Park HM. Potential adverse effect of high survey dose of I-131 administered prior to I-131 therapy in the management of differentiated thyroid cancers. In Schmidt H, Van Der Schoot JB, editors. Nuclear Medicine: The State of the Art of Nuclear Medicine in Europe. Schattauer, Stuttgart, Germany, 1991:340-342.
3. Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of I-131. Thyroid 1994; 4:49-54.
4. Park HM. The stunning effect in radioiodine therapy of thyroid cancer. Nucl Med Ann 2001; 49-67.
5. McDougall IR. 74 MBq I-131 does not prevent uptake of therapeutic doses of I-131 in differentiated thyroid cancer. Nucl Med Comm 1997; 18:505-512.
6. Medvedec M, Pavlinovic Z, Dodig D. 74 MBq radioiodine I-131 does prevent uptake of therapeutic activity of I-131 in residual thyroid tissue. Eur J Nucl Med 1999; 26:1013.
7. Huic D, Medvedec M, Dodig D, et al. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I. Nucl Med Comm 1996; 17:839-842.
8. McMenemin RM, Hilditch TE, Dempsey MF, Reed NS. Thyroid stunning after 131I diagnostic whole-body scanning. J Nucl Med 2001; 42:986-987.
9. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13:277-279.
10. Huic D, Medvedec M, Dodig D, et al. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose I-131. Nucl Med Comm 1996; 17:839-842.
11. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of I-131 after 185 MBq I-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. E ur J Nucl Med 1998; 25:242-246.
12. Postgard P, Himmelman J, Lindencrona L, et al. Stunning of iodide transport by I-131 irradiation in cultured thyroid epithelial cells. J Nucl Med 2002; 43:828-834.
13. Cholewinski S, Yoo K, Klieger P, O'Mara R. Absence of thyroid stun ning after diagnostic whole-body scanning w ith 185 MBq I-131. J Nucl Med 2000; 41:1198-1202.
14. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology 2004; 232:527-533.
15. Sabri O, Zimny M, Schreckenberger M, et al. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000; 27:1591-1597.
16. Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004; 45:619-625.
17. Medvedec M, Grosev D, Loncaric S, et al. As soon as possible is already too late. J Nucl Med 2001; 42:322P.
18. Gerard S. The role of I-123 in the management of differentiated thyroid cancer. CME symposium presented at the 74th Annual Meeting of the American Thyroid Association, October 11, 2002.
19. Koch W, Knesewitsch P, Tatsch K, Hahn K. Stunning effects in radioiodine therapy of thyroid carcinoma: existence, clinical effects and ways out. Nuclearmedizin 2003; 42:10-14.
20. Park H, Park Y, Zhou X. Detection of thyroid remnant/metastasis without stunning: An ongoing dilemma. Thyroid 1997; 7:277-280.
21. Muratet J, Daver A, Minier J, Larra F. Influence of scanning doses of I-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39:1556-1550.
22. Lees W, Mansberg R, Roberts J, et al. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq I-131. Eur J Nucl Med 2002; 29:1421-1427.
23. Morris LF, Waxman AD, Braunstein GD. The non-impact of thyroid stunning: Remnant ablation rates in I-131-scanned and non-scanned individuals. J Clin Endocrinol Metab 2001; 86:3507-3511.
24. 132I as sodium iodide. J Nucl Med 1975; 16: 857-860.
25. Waxman A, Ramanna L, Chapman N, et al. S ignificance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication. J Nucl Med 1981; 22:861-865.
26. Gerard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med 2002; 27:1-8.
27. Gulzar Z, Jana S, Young I, et al. Neck and whole-body scanning with a 5 mCi (185 MBq) dose of I-123 as diagnostic tracer in patients with well-differentiated thyroid cancer. Endocr Pract 2001; 7:244-249.
28. Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26:6-9.
29. Sarkar SD, Kalapparambath TP, Palestro CJ. Comparison of I-123 and I-131 for whole-body imaging in thyroid cancer. J Nucl Med 2002; 43:632-634.
30. Bautovich GJ, Towson JE, Eberl S, et al. Comparison of iodine-123 and iodine-131 as a scanning agent for the detection of metastatic thyroid cancer. J Nucl Med 1997; 38:150P-151P.
31. Shankar LK, Yamamoto AJ, Alavi A, Mandel SJ. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2002; 43:72-76.
32. De Geus-Oei LF, Pauwels EKJ, Stokkel MPM. A comparison between low and high dose I-123 WBS in the follow-up of thyroid cancer. E ur J Nucl Med 2000; 27(Suppl):931.
33. Kalinyak JE. I-123 as a diagnostic tracer in the management of thyroid cancer. Editorial. Nucl Med Comm 2002; 23:509-511.
34. Berbano R, Naddaf S, Echemendia E, et al. Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer. Endocr Pract 1998; 4:11-16.
35. Anderson GS, Fish S, Nakhoda K, et al. Comparison of I-123 and I-131 for whole-body imaging after stimulation by recombinant human thyrotropin: a preliminary report. Clin Nucl Med 2003; 28: 93-96.
36. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest 1999; 22:30-34.
37. Berg G, Lindstedt G, Suurkula M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002; 25:44-52.
38. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioio-dine thyroid remnant ablation. J Nucl Med 2002; 43:1482-1488.
39. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 2003; 30:1077-1086.
40. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. E ur J Nucl Med Mol Imaging 2003; 30:1371-1377.
41. Rawson RW, Rall JE, Peacock W. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol Metab 1951; 11:1128-1131.
42. Pluijmen MJHM, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol 2003; 58:428-435.